(1R,2R)-2-benzoylcyclohexanecarboxylic acid | 820991-06-8

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (1R,2R)-2-benzoylcyclohexanecarboxylic acid
• 英文别名: trans-2-Benzoylcyclohexane-1-carboxylic acid；(1R,2R)-2-benzoylcyclohexane-1-carboxylic acid
• CAS: 820991-06-8
• 化学式: C₁₄H₁₆O₃
• 分子量: 232.279
• InChiKey: FLPQLUGZLPSVOG-VXGBXAGGSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  54.4
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (1R,2R)-2-benzoylcyclohexanecarboxylic acid 在 盐酸 、 硫酸 、 mercury dichloride 、 锌 作用下， 生成 (4aS,9aR)-(+)-1,2,3,4,4a,9,9a,10-octahydro-9-anthracenone
  参考文献：
  名称：

  1000. 2-硝基蒽和N-羟基-2-蒽胺的合成

  摘要：

  DOI：

  10.1039/jr9650005377
• 作为产物：
  描述：

  alkaline earth salt of/the/ methylsulfuric acid 在 sodium hydroxide 作用下， 生成 (1R,2R)-2-benzoylcyclohexanecarboxylic acid
  参考文献：
  名称：

  制备碱性取代的哒嗪-6-酮。合成药物研究，第5部分

  摘要：

  从碱取代的肼开始，通过已知方法制备了许多碱取代的哒嗪酮。在提供起始原料时，可以将熔点为139-140°的已知的2-苯甲酰基-环己烷-1-甲酸分配为顺式；还制备了差向异构体反式衍生物。

  DOI：

  10.1002/hlca.19590420721

文献信息

• Silver-Catalyzed Decarboxylative Bromination of Aliphatic Carboxylic Acids
  作者：Xinqiang Tan、Tao Song、Zhentao Wang、He Chen、Lei Cui、Chaozhong Li

  DOI：10.1021/acs.orglett.7b00439

  日期：2017.4.7

  The silver-catalyzed Hunsdiecker bromination of aliphatic carboxylic acids is described. With Ag(Phen)2OTf as the catalyst and dibromoisocyanuric acid as the brominating agent, various aliphatic carboxylic acids underwent decarboxylative bromination to provide the corresponding alkyl bromides under mild conditions. This method not only is efficient and general but also enjoys wide functional group

  描述了银催化的脂肪族羧酸的Hunsdiecker溴化。以Ag（Phen）2 OTf为催化剂，二溴异氰尿酸为溴化剂，各种脂肪族羧酸经过脱羧溴化，在温和条件下提供相应的烷基溴化物。该方法不仅高效通用，而且具有广泛的功能组兼容性。提出了涉及Ag（II）中间体的氧化自由基机理。
• [EN] ALPHA-AMINO BORONIC ACID DERIVATIVES, SELECTIVE IMMUNOPROTEASOME INHIBITORS<br/>[FR] DÉRIVÉS D'ACIDE ALPHA-AMINO BORONIQUE, INHIBITEURS SÉLECTIFS DE L'IMMUNOPROTÉASOME
  申请人：ARES TRADING SA

  公开号：WO2013092979A1

  公开（公告）日：2013-06-27

  The present invention provides compounds of Formula (I) as inhibitors of LMP7 for the treatment of autoimmune and inflammatory diseases. In formula (I), Rb and Rc are independently selected from one another from H or C1-C6-alkyl; whereby Rb and Rc may be linked to form a 5 or 6 membered-ring containing the oxygen atoms to which they are linked; Q denotes Ar, Het or cycloalkyl; R1 R2 independently from each other denotes H, ORa, Hal, C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; Y denotes CR 3R4, preferably CH2 or C(CH3)2; R 3, R4 independently of one another denote H or C1-C6-alkyl; L denotes L1 or L2 or alkyl; n is an integer selected from 0 to 3; L 1 is Q1-CO-M- wherein Q 1 is Ar or Het, preferably, phenyl, naphthyl or pyridine, optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; L2 is Q2-M- wherein Q 2 is a fused bicyclic system containing 1 nitrogen atom and 1 to 3 additional groups independently selected from O, S, N, or CO, and wherein at least one of the rings is aromatic whereby the fused bicyclic system is optionally substituted with 1 to 5 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; or Q 2 is unsaturated or aromatic 5 membered-ring system containing 1 to 3 heteroatoms selected from N, O, S and CO, and optionally substituted with a phenyl ring or pyridine ring whereby phenyl ring and pyridine ring are optionally substituted with 1 to 4 groups independently selected from ORa, Hal, phenyl, and C1-C6-alkyl wherein 1 to 5 H atoms may be independently replaced by OH or Hal; M is a linear or branched alkylene having 1 to 5 carbon atoms wherein 1 or 2 H atoms may be replaced by OR a or a phenyl ring optionally substituted with 1 to 5 groups independently selected from Hal, ORa, and C1-C6-alkyl optionally substituted with 1 to 5 groups independently selected from OH, and Hal; or M denotes a cycloalkylene having 3 to 7 carbon atoms; or M denotes a thiazolidinyl group; R a is H or C1-C6-alkyl wherein 1 to 5 H atom may be independently replaced by OH or Hal; Ar denotes a 6 membered-aromatic carbocyclic ring optionally fused with another carbocyclic saturated, unsaturated or aromatic ring having 5 to 8 carbon atoms; Het denotes a 5- or 6-membered saturated, unsaturated or aromatic heterocyclic ring having 1 to 3 heteroatoms independently selected from N, N+O-, O, S, SO, and SO 2, and optionally fused with another saturated, unsaturated or aromatic ring having 5 to 8 atoms and optionally containing 1 to 3 heteroatoms selected from N, O, and S; Hal denotes CI, Br, I of F; preferably CI or F.

  本发明提供了化合物的公式（I）作为LMP7的抑制剂，用于治疗自身免疫和炎症性疾病。在公式（I）中，Rb和Rc分别独立地从H或C1-C6-烷基中选择；其中Rb和Rc可以连接形成一个含有它们连接的氧原子的5或6元环；Q表示Ar，Het或环烷基；R1和R2彼此独立地表示H，ORa，Hal，C1-C6-烷基，其中1到5个H原子可以独立地被OH或Hal替换；Y表示CR 3R4，优选CH2或C(CH3)2；R3，R4彼此独立地表示H或C1-C6-烷基；L表示L1或L2或烷基；n是从0到3选择的整数；L1是Q1-CO-M-，其中Q1是Ar或Het，优选苯基，萘基或吡啶基，可选地取代为1到5个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；L2是Q2-M-，其中Q2是含有1个氮原子和1到3个额外基团的融合双环系统，独立选择自O，S，N或CO，其中至少一个环是芳香环，融合双环系统可选地取代为1到5个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；或Q2是不饱和或芳香的含有1到3个从N，O，S和CO中选择的杂原子的5元环系统，并可选地取代为苯环或吡啶环，其中苯环和吡啶环可选地取代为1到4个从ORa，Hal，苯基和C1-C6-烷基中独立选择的基团，其中1到5个H原子可以独立地被OH或Hal替换；M是具有1到5个碳原子的线性或支链烷基，其中1或2个H原子可以被ORa或可选地取代为1到5个从Hal，ORa和C1-C6-烷基中独立选择的基团，可选地取代为1到5个从OH和Hal中独立选择的基团；或M表示具有3到7个碳原子的环烷基；或M表示噻唑烷基；Ra是H或C1-C6-烷基，其中1到5个H原子可以独立地被OH或Hal替换；Ar表示一个6元芳香碳环，可选地与另一个含有5到8个碳原子的碳环饱和、不饱和或芳香环融合；Het表示一个含有1到3个从N，N+O-，O，S，SO和SO2中独立选择的杂原子的5或6元饱和、不饱和或芳香杂环，可选地与另一个含有5到8个原子的饱和、不饱和或芳香环融合，并可选地含有1到3个从N，O和S中选择的杂原子；Hal表示CI，Br，I或F；优选CI或F。
• Resolution of Carboxylic Acids Using Copper(I)-Promoted Removal of Propargylic Esters under Neutral Conditions
  作者：Partha Ghosh、Jeffrey Aubé

  DOI：10.1021/jo200433w

  日期：2011.5.20

  A method for the optical resolution of carboxylic acids is described. Condensation of racemic carboxylic acids with chiral terminal propargyl alcohols gave separable diastereomeric esters. Chromatographic separation followed by heating the individual diastereomers in methanol with catalytic copper(I) halide regenerated the carboxylic acids in good yields and in enantiomeric ratios of ≥94%. This method

  描述了羧酸的光学拆分方法。外消旋羧酸与手性末端炔丙醇缩合得到可分离的非对映体酯。色谱分离，然后在甲醇中加热单个非对映异构体和催化卤化铜 (I)，以良好的收率和≥94% 的对映体比率再生羧酸。该方法对于拆分与常规酯水解不相容的羧酸特别有用。
• Silver-Catalyzed Decarboxylative Allylation of Aliphatic Carboxylic Acids in Aqueous Solution
  作者：Lei Cui、He Chen、Chao Liu、Chaozhong Li

  DOI：10.1021/acs.orglett.6b00802

  日期：2016.5.6

  Direct decarboxylative radical allylation of aliphatic carboxylic acids is described. With K2S2O8 as the oxidant and AgNO3 as the catalyst, the reactions of aliphatic carboxylic acids with allyl sulfones in aqueous CH3CN solution gave the corresponding alkenes in satisfactory yields under mild conditions. This site-specific allylation method is applicable to all primary, secondary, and tertiary alkyl

  描述了脂肪族羧酸的直接脱羧自由基烯丙基化。以K 2 S 2 O 8为氧化剂，AgNO 3为催化剂，脂肪族羧酸与烯丙基砜在CH 3 CN水溶液中的反应在温和条件下以令人满意的收率得到了相应的烯烃。此位点特定的烯丙基化方法适用于所有伯，仲和叔烷基酸，并具有广泛的官能团相容性。
• Metal-Free Arylation-Lactonization Sequence of <i>γ</i> -Alkenoic Acids Using Anilines as Aryl Radical Precursors
  作者：Diego Felipe-Blanco、Jose C. Gonzalez-Gomez

  DOI：10.1002/ejoc.201901679

  日期：2019.12.19

  This work was generously supported by the Spanish Ministerio de Economia y Competitividad (MINECO; grant no. CTQ2017–88171-P) and the Generalitat Valenciana (GV; grant no. AICO/2017/007).

  这项工作得到了西班牙经济和竞争部长 (MINECO; 授予号 CTQ2017–88171-P) 和 Generalitat Valenciana (GV; 授予号 AICO/2017/007) 的慷慨支持。